Zacks: Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.43 Million

Analysts expect that Charles River Laboratories Intl. Inc (NYSE:CRL) will announce sales of $476.43 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Charles River Laboratories Intl.’s earnings, with the lowest sales estimate coming in at $468.42 million and the highest estimate coming in at $484.00 million. Charles River Laboratories Intl. reported sales of $466.79 million during the same quarter last year, which indicates a positive year-over-year growth rate of 2.1%. The business is expected to report its next quarterly earnings report on Tuesday, February 13th.

On average, analysts expect that Charles River Laboratories Intl. will report full year sales of $476.43 million for the current financial year, with estimates ranging from $1.85 billion to $1.86 billion. For the next year, analysts expect that the business will report sales of $1.99 billion per share, with estimates ranging from $1.97 billion to $2.00 billion. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories Intl.’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 earnings per share.

Several research firms have weighed in on CRL. Jefferies Group boosted their price objective on Charles River Laboratories Intl. from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Argus began coverage on Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price objective on the stock. SunTrust Banks reissued a “buy” rating and issued a $113.00 price objective on shares of Charles River Laboratories Intl. in a research report on Friday, November 17th. Bank of America cut their price objective on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Finally, Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a research report on Tuesday, October 24th. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $112.58.

In other Charles River Laboratories Intl. news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. Also, Director C Richard Reese sold 10,227 shares of the business’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the sale, the director now owns 51,444 shares in the company, valued at $5,267,865.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,195,673 shares of company stock worth $2,914,046. Corporate insiders own 2.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. M&T Bank Corp raised its stake in shares of Charles River Laboratories Intl. by 1.8% during the 2nd quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock valued at $441,000 after purchasing an additional 76 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Charles River Laboratories Intl. by 1.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 22,974 shares of the medical research company’s stock valued at $2,324,000 after purchasing an additional 242 shares during the period. Riverhead Capital Management LLC raised its stake in shares of Charles River Laboratories Intl. by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Charles River Laboratories Intl. by 2.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 14,256 shares of the medical research company’s stock valued at $1,442,000 after purchasing an additional 291 shares during the period. Finally, Public Employees Retirement System of Ohio raised its stake in shares of Charles River Laboratories Intl. by 1.5% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 22,383 shares of the medical research company’s stock valued at $2,264,000 after purchasing an additional 330 shares during the period. Institutional investors own 95.87% of the company’s stock.

Shares of Charles River Laboratories Intl. (NYSE:CRL) traded up $1.22 during trading hours on Monday, hitting $107.89. The company had a trading volume of 407,500 shares, compared to its average volume of 371,285. The stock has a market capitalization of $4,990.00, a PE ratio of 26.38, a price-to-earnings-growth ratio of 1.58 and a beta of 0.88. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories Intl. has a one year low of $77.61 and a one year high of $119.05.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.43 Million” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/22/zacks-analysts-expect-charles-river-laboratories-intl-inc-crl-will-announce-quarterly-sales-of-476-43-million.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply